Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Avalon GloboCare ( (ALBT) ).
On April 29, 2025, Avalon GloboCare Corp. and YOOV Group Holding Limited announced the filing of a Registration Statement on Form S-4 with the SEC in connection with their proposed merger. This merger aims to create a publicly-traded company that will leverage YOOV’s AI automation solutions to optimize business operations across various industries. The merger’s completion is contingent upon stockholder approval and Nasdaq’s listing approval, and it is expected to enhance service delivery and reduce costs for organizations.
More about Avalon GloboCare
Avalon GloboCare Corp. is a commercial-stage company focused on developing and delivering precision diagnostic consumer products and advancing intellectual property in cellular therapy. The company markets the KetoAir™ breathalyzer device, registered as a Class I medical device with the U.S. Food and Drug Administration, and plans to expand its diagnostic applications. Avalon also owns and operates commercial real estate.
YTD Price Performance: 18.08%
Average Trading Volume: 85,550
Technical Sentiment Signal: Strong Buy
Current Market Cap: $6.69M
For detailed information about ALBT stock, go to TipRanks’ Stock Analysis page.